Technical specifcation for diagnosis and treatment of hyperuricemia after renal transplantation in China(2019 edition)

Branch of Organ Transplantation of Chinese Medical Association

doi:10.3969/j.issn.1674-7445.2019.01.002

Volume 10 Issue 1

Jan. 2019

Turn off MathJax

Article Contents

Article Navigation > ORGAN TRANSPLANTATION > 2019 > 10(1): 10-15

Branch of Organ Transplantation of Chinese Medical Association. Technical specifcation for diagnosis and treatment of hyperuricemia after renal transplantation in China(2019 edition)[J]. ORGAN TRANSPLANTATION, 2019, 10(1): 10-15. doi: 10.3969/j.issn.1674-7445.2019.01.002

Citation:

PDF( 822 KB)

Technical specifcation for diagnosis and treatment of hyperuricemia after renal transplantation in China(2019 edition)

doi: 10.3969/j.issn.1674-7445.2019.01.002

Branch of Organ Transplantation of Chinese Medical Association

Received Date: 2018-11-01
Available Online: 2021-01-19
Publish Date: 2019-01-15

Abstract

FullText(HTML)

References(35)

References

[1]	BELLOMO G.Asymptomatic hyperuricemia following renal transplantation[J].World J Nephrol, 2015, 4(3):324-329.DOI: 10.5527/wjn.v4.i3.324.
[2]	KALANTAR E, KHALILI N, HOSSIENI MS, et al.Hyperuricemia after renal transplantation[J].Transplant Proc, 2011, 43(2):584-585.DOI: 10.1016/j.transproceed.2011.01.062.
[3]	MALHEIRO J, ALMEIDA M, FONSECA I, et al.Hyperuricemia in adult renal allograft recipients:prevalence and predictors[J].Transplant Proc, 2012, 44(8):2369- 2372.DOI: 10.1016/j.transproceed.2012.07.033.
[4]	NUMAKURA K, SATOH S, TSUCHIYA N, et al.Hyperuricemia at 1 year after renal transplantation, its prevalence, associated factors, and graft survival[J].Transplantation, 2012, 94(2):145-151.DOI: 10.1097/TP.0b013e318254391b.
[5]	CLIVE DM.Renal transplant-associated hyperuricemia and gout[J].J Am Soc Nephrol, 2000, 11(5):974-979. http://d.old.wanfangdata.com.cn/NSTLQK/NSTL_QKJJ028136156/
[6]	KIM KM, KIM SS, HAN DJ, et al.Hyperuricemia in kidney transplant recipients with intact graft function[J].Transplant Proc, 2010, 42(9):3562-3567.DOI: 10.1016/j.transproceed.2010.07.104.
[7]	中国医师协会肾脏内科医师分会.中国肾脏疾病高尿酸血症诊治的实践指南(2017版)[J].中华医学杂志, 2017, 97(25):1927-1936.DOI:10.3760/cma.j.issn.0376- 2491.2017.25.003. Branch of Kidney Physicians of Chinese Physicians Association.Guidelines for the diagnosis and treatment of hyperuricemia in renal diseases in China (2017 edition)[J].Natl Med J China, 2017, 97(25):1927-1936.DOI:10.3760/cma.j.issn.0376- 2491.2017.25.003.cma.j.issn.0376-2491.2017.25.003.
[8]	BAHN A, HAGOS Y, REUTER S, et al.Identification of a new urate and high affinity nicotinate transporter, hOAT10 (SLC22A13)[J].J Biol Chem, 2008, 283(24):16332- 16341.DOI: 10.1074/jbc.M800737200.
[9]	KANBAY M, AKCAY A, HUDDAM B, et al.Influence of cyclosporine and tacrolimus on serum uric acid levels in stable kidney transplant recipients[J].Transplant Proc, 2005, 37(7):3119-3120. doi: 10.1016/j.transproceed.2005.08.042
[10]	ZAWIASA A, SZKLAREK-KUBICKA M, FIJAŁKOWSKAMORAWSKA J, et al.Effect of oral fructose load on serum uric acid and lipids in kidney transplant recipients treated with cyclosporine or tacrolimus[J].Transplant Proc, 2009, 41(1):188-191.DOI: 10.1016/j.transproceed.2008.10.038.
[11]	OLYAEI AJ, DE MATTOS AM, BENNETT WM.Nephrotoxicity of immunosuppressive drugs:new insight and preventive strategies[J].Curr Opin Crit Care, 2001, 7(6):384-389. doi: 10.1097/00075198-200112000-00003
[12]	EL-SHEIKH AA, VAN DEN HEUVEL JJ, KOENDERINK JB, et al.Effect of hypouricaemic and hyperuricaemic drugs on the renal urate efflux transporter, multidrug resistance protein 4[J].Br J Pharmacol, 2008, 155(7):1066-1075.DOI: 10.1038/bjp.2008.343.
[13]	YOSHIMURA N, USHIGOME H, MATSUYAMA M, et al.The efficacy and safety of high-dose mizoribine in ABO-incompatible kidney transplantation using antiCD20 and anti-CD25 antibody without splenectomy treatment[J].Transplant Proc, 2012, 44(1):140-143.DOI: 10.1016/j.transproceed.2011.12.009.
[14]	TAKAHARA S, TAKAHASHI K, AKIYAMA T, et al.Randomized comparative trial of mizoribine versus mycophenolate mofetil in combination with tacrolimus for living donor renal transplantation[J].Clin Exp Nephrol, 2013, 17(6):899-904.DOI: 10.1007/s10157-013-0780-1.
[15]	SHI Y, LIU H, CHEN XG, et al.Comparison of mizoribine and mycophenolate mofetil with a tacrolimus-based immunosuppressive regimen in living-donor kidney transplantation recipients:a retrospective study in China[J].Transplant Proc, 2017, 49(1):26-31.DOI: 10.1016/j.transproceed.2016.10.018.
[16]	SUGITANI A, KITADA H, OTA M, et al.Revival of effective and safe high-dose mizoribine for the kidney transplantation[J].Clin Transplant, 2006, 20(5):590-595. doi: 10.1111/ctr.2006.20.issue-5
[17]	NISHIMURA K, UCHIDA K, YUZAWA K, et al.Excellent results with high-dose mizoribine combined with cyclosporine, corticosteroid, and basiliximab in renal transplant recipients:multicenter study in Japan[J].Transplant Proc, 2012, 44(1):147-149.DOI: 10.1016/j.transproceed.2011.11.015.
[18]	IWANAGA T, SATO M, MAEDA T, et al.Concentration-dependent mode of interaction of angiotensin Ⅱ receptor blockers with uric acid transporter[J].J Pharmacol Exp Ther, 2007, 320(1):211-217. http://www.ncbi.nlm.nih.gov/pubmed/17043154
[19]	HONG Q, QI K, FENG Z, et al.Hyperuricemia induces endothelial dysfunction via mitochondrial Na⁺/Ca²⁺ exchanger-mediated mitochondrial calcium overload[J].Cell Calcium, 2012, 51(5):402-410.DOI: 10.1016/j.ceca.2012.01.003.
[20]	SAITO I, SARUTA T, KONDO K, et al.Serum uric acid and the renin-angiotensin system in hypertension[J].J Am Geriatr Soc, 1978, 26(6):241-247. doi: 10.1111/jgs.1978.26.issue-6
[21]	KANELLIS J, WATANABE S, LI JH, et al.Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2[J].Hypertension, 2003, 41(6):1287-1293. doi: 10.1161/01.HYP.0000072820.07472.3B
[22]	NAKAGAWA T, MAZZALI M, KANG DH, et al.Hyperuricemia causes glomerular hypertrophy in the rat[J].Am J Nephrol, 2003, 23(1):2-7. doi: 10.1159/000066303
[23]	FEIG DI, KANG DH, NAKAGAWA T, et al.Uric acid and hypertension[J].Curr Hypertens Rep, 2006, 8(2):111-115. doi: 10.1007/s11906-006-0005-z
[24]	HUANG Y, LI YL, HUANG H, et al.Effects of hyperuricemia on renal function of renal transplant recipients:a systematic review and Meta-analysis of cohort studies[J].PLoS One, 2012, 7(6):e39457.DOI: 10.1371/journal.pone.0039457.
[25]	CHOI JY, KWON OJ.The association between serum uric acid levels at 3 months after renal transplantation and the graft outcome in living donor renal transplantation[J].Transplant Proc, 2013, 45(4):1548-1552.DOI: 10.1016/j.transproceed.2012.10.062.
[26]	WENG SC, SHU KH, TARNG DC, et al.Uric acid is highly associated with kidney allograft survival in a timevarying analysis[J].Transplant Proc, 2014, 46(2):505- 510.DOI: 10.1016/j.transproceed.2013.09.038.
[27]	MIN SI, YUN IJ, KANG JM, et al.Moderate-to-severe early-onset hyperuricaemia:a prognostic marker of longterm kidney transplant outcome[J].Nephrol Dial Transplant, 2009, 24(8):2584-2590.DOI: 10.1093/ndt/gfp192.
[28]	中华医学会内分泌学分会.高尿酸血症和痛风治疗的中国专家共识[J].中华内分泌代谢杂志, 2013, 29(11):913- 920.DOI: 10.3760/cma.j.issn.1000-6699.2013.11.001. Branch of Endocrinology of Chinese Medical Association.Chinese experts consensus on treatment of hyperuricemia and gout[J].Chin J Endocrinol Metabol, 2013, 29(11):913- 920.DOI: 10.3760/cma.j.issn.1000-6699.2013.11.001.
[29]	高尿酸血症相关疾病诊疗多学科共识专家组.中国高尿酸血症相关疾病诊疗多学科专家共识[J].中华内科杂志, 2017, 56(3):235-248.DOI: 10.3760/cma.j.issn.0578-1426.2017.03.021. Expert Group of Multi-Disciplinary Consensus on the Diagnosis and Treatment of Hyperuricemia and its Related Diseases.Chinese multi-disciplinary consensus on the diagnosis and treatment of hyperuricemia and its related diseases[J].Chin J Intern Med, 2017, 56(3):235-248.DOI: 10.3760/cma.j.issn.0578-1426.2017.03.021.
[30]	GOICOECHEA M, DE VINUESA SG, VERDALLES U, et al.Effect of allopurinol in chronic kidney disease progression and cardiovascular risk[J].Clin J Am Soc Nephrol, 2010, 5(8):1388-1393.DOI: 10.2215/CJN.01580210.
[31]	BECKER MA, SCHUMACHER HR JR, WORTMANN RL, et al.Febuxostat compared with allopurinol in patients with hyperuricemia and gout[J].N Engl J Med, 2005, 353(23):2450-2461. doi: 10.1056/NEJMoa050373
[32]	ENOMOTO A, KIMURA H, CHAIROUNGDUA A, et al.Molecular identification of a renal urate anion exchanger that regulates blood urate levels[J].Nature, 2002, 417(6887):447-452. doi: 10.1038/nature742
[33]	TALAAT KM, EL-SHEIKH AR.The effect of mild hyperuricemia on urinary transforming growth factor beta and the progression of chronic kidney disease[J].Am J Nephrol, 2007, 27(5):435-440. doi: 10.1159/000105142
[34]	JOHNSON RJ, KANG DH, FEIG D, et al.Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease?[J].Hypertension, 2003, 41(6):1183-1190. doi: 10.1161/01.HYP.0000069700.62727.C5
[35]	SÁNCHEZ-LOZADA LG, NAKAGAWA T, KANG DH, et al.Hormonal and cytokine effects of uric acid[J].Curr Opin Nephrol Hypertens, 2006, 15(1):30-33. doi: 10.1097/01.mnh.0000199010.33929.7f

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Tables(1)

Get Citation

PDF

XML

Article Metrics

Article views (336) PDF downloads(103)

Technical specifcation for diagnosis and treatment of hyperuricemia after renal transplantation in China(2019 edition)

doi: 10.3969/j.issn.1674-7445.2019.01.002

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Export File

Citation

Format

Content